BXRX:NSD-Baudax Bio Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 0.76

Change

-0.03 (-3.78)%

Market Cap

USD 4.88M

Volume

0.24M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


BXRX Stock Forecast & Price:
Based on the Baudax Bio Inc stock forecasts from 0 analysts, the average analyst target price for Baudax Bio Inc is not available over the next 12 months. Baudax Bio Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Baudax Bio Inc is Bearish, which is based on 1 positive signals and 7 negative signals. At the last closing, Baudax Bio Inc’s stock price was USD 0.76. Baudax Bio Inc’s stock price has changed by -1.69% over the past week, -12.88% over the past month and -96.03% over the last year.

No recent analyst target price found for Baudax Bio Inc
No recent average analyst rating found for Baudax Bio Inc

About Baudax Bio Inc (BXRX:NSD)

Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its produ ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-08-10 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Inc

-3.06 (-1.02%)

USD75.25B 29.60 15.72
MRNA Moderna Inc

+3.13 (+1.83%)

USD71.57B 5.79 4.08
REGN Regeneron Pharmaceuticals Inc

+19.34 (+3.11%)

USD67.87B 12.49 9.34
BNTX BioNTech SE

+3.71 (+2.36%)

USD40.37B 3.26 2.01
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
SGEN Seagen Inc

+0.05 (+0.03%)

USD32.39B 55.02 -46.79
RPRX Royalty Pharma Plc

+0.25 (+0.57%)

USD29.52B 42.40 20.35
ALNY Alnylam Pharmaceuticals Inc

+8.63 (+3.86%)

USD27.16B N/A -34.32
GMAB Genmab AS

+0.56 (+1.59%)

USD22.96B 73.23 6.37
ARGX argenx NV ADR

+0.21 (+0.06%)

USD20.61B N/A -20.22

ETFs Containing BXRX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -90.09% 2% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -90.09% 2% F 1% F
Trailing 12 Months  
Capital Gain -96.10% 2% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -96.10% 2% F 1% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -51.05% 1% F N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -51.05% 1% F N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 40.57% 67% D+ 36% F
Risk Adjusted Return -125.81% 2% F 1% F
Market Capitalization 4.88M 1% F 1% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -99,999.99 89% B+ 97% A+
Price/Book Ratio 0.51 90% A- 93% A
Price / Cash Flow Ratio -0.10 11% F 50% F
EV/EBITDA -0.13 37% F 58% F
Management Effectiveness  
Return on Equity -358.12% 8% F 4% F
Return on Invested Capital -235.95% 5% F 5% F
Return on Assets -54.79% 12% F 4% F
Debt to Equity Ratio 47.70% 34% F 40% F
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 0.91 82% B- 80% B-
Short Percent 1.80% 69% D+ 62% D-
Beta 1.53 34% F 23% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.